Phase 1 Backs Phase 3 Dose for Lung Cancer Drug
A Phase 1 clinical trial for an investigational lung cancer drug has shown promising efficacy and safety in patients with EGFR-mutated non-small cell lung cancer. These results support the advancement of the 2.5 mg/kg dose into a global Phase 3 registrational study.
Why it matters
Advancing this drug to Phase 3 trials offers potential new treatment options for patients with limited therapeutic alternatives for advanced lung cancer.
(SEOUL, Republic of Korea - September 12 th , 6:15 p.m. Korea Standard Time) - An investigational EGFR x HER3 antibody-drug conjugate demonstrated promising efficacy with a tolerable safety profile in patients with previously treated EGFR-mutated non-small cell lung cancer (NSCLC), supporting selection of the 2.5 mg/kg dose for evaluation in the global Phase 3 IZABRIGHT-Lung01 registrational study.
These results will be presented at the International Association for the Study of Lung Cancer (IASLC) 2026 World Conference on Lung Cancer (WCLC) in Seoul, Republic of Korea.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in